1995 growth of pacemaker market estimated at 13%
This article was originally published in Clinica
Executive Summary
US broker Morgan Stanley forecasts sustainable growth for the worldwide pacemaker market in the high single-digit range after a strong 1995 rise of around 13%. Analyst Glenn Reicin estimates the 1995 pacemaker market, one of the largest markets in medical technology, at $2,300 million, half of which are US sales.
You may also be interested in...
Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans
Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.